Consequences and limits J Clin Densitom 2:37–44CrossRef 16. Kanis JA,

Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–97PubMedCrossRef 17. WHO Collaborating Centre for Metabolic Bone Diseases (2008) FRAX WHO fracture risk assessment tool. Available at: http://​www.​shef.​ac.​uk/​FRAX/​. Accessed 27 April 2011 18. Briot K, CBL-0137 order Tremollieres F, Thomas T et al (2007) How long should patients take medications for postmenopausal P5091 solubility dmso osteoporosis? Joint Bone Spine 74:24–31PubMedCrossRef 19. Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–99PubMedCrossRef 20. Kanis JA, Johansson SB-715992 solubility dmso H, Oden A et al. (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int In press 21. McCloskey E, Johansson H, Oden A et al. (2011) Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed

with FRAX. Abstract OC15. Osteoporos Int 22 (suppl 1):S103 22. McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind,

placebo-controlled randomised study. Osteoporos Int 20:811–7PubMedCrossRef 23. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–82PubMedCrossRef 24. Vittinghoff Tobramycin E, McCulloch CE, Woo C et al (2010) Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med 29:1127–36PubMed”
“Introduction Osteoarthritis (OA) and osteoporosis (OP) are two common, age-related disorders that are associated with considerable morbidity. The relationship between OA and OP has been examined in both community studies and case series. Studies of adult twins have shown an association between birth weight and bone mineral density (BMD) [1]. The twin studies have also shown that lumbar degenerative disc disease is similar in many ways to OA with evidence that degenerative disc disease is associated with a higher BMD at the hip and lumbar spine [2]. Data from Finland have shown that persons with poor height gain during childhood have an increase in their risk of hip fracture several decades later [3]. It has been suggested that the presence of OA protects against osteoporosis-related fractures [4–7], and that there is an inverse relationship between the two conditions [8–11].